

CRT

Exciting research has been completed at University of Innsbruck, Austria by CRT research partners that clearly show that shockwaves communicate with cells via TLR3 receptors (Toll Like Receptors). Pharmaceutical companies have spent billions attempting to communicate with these receptors as they are known to control the auto immune system. This opens up a completely new and exciting field for our company. Additionally, the research team has proven that shockwaves recruit mass amounts of stem cells from the bone marrow to the treated pathology and cause the stem cells to differentiate as well. The team used a mouse model where the donor mice stem cells were all fluorescent green. The treatment mice bone marrow was killed via radiation, and the green donor mice cells were transplanted. The treatment mice then underwent ligation of the coronary artery causing massive ischemia in the heart. After the scar on the heart matured, the heart was treated with shockwaves and the ischemic area sampled via harvest and biopsy. The biopsies showed that green fluorescent stem cells had migrated to the ischemic heart tissue from the bone marrow and formed brand new capillaries and small vessels. This study has been submitted to one of the world's leading journals and we hope to see it published soon.

Based on these findings, and others, we have funded the purchase of new disposable cardio probes for Innsbruck, and the researchers have negotiated with the University to begin clinical trials this summer that should lead to European approval of the technology. CRT has reached preliminary agreement with the group to become the exclusive distributor of this technology in the United States. We are again, actively seeking a strategic partner to commit to the FDA approval path to gain approval in the United States.

K-1's

TRT and CRT have closed out the 2013 financials and delivered all relevant information to outside tax preparers. We have been assured that K-1's will be mailed to shareholders by the end of February, latest. Please note that over the last 2 years nearly 20% of the forms have been returned to us as undeliverable as shareholders have moved and not notified us of the address change. If you have moved, please contact us by phone or mail immediately to be certain that we have your new address.

Tissue Regeneration Technologies, LLC
130 Arnold Mill Park, Woodstock, GA 30188
Tel: (770) 966-1315 ▪ Tdd: (877) 966-1315
Fax: (770) 592-8910 ▪ Web: www.trtllc.com

LithoGold / MTS

We have reached an agreement in principle with MTS and their suppliers to complete the LG ultrasound project in time to demonstrate the upgrade at the AUA. We were shown drawings of the ultrasound upgrade and we were impressed by the simplicity and ease of use. We also agreed to add an over table treatment option to the LithoGold and a few other features based on feedback from our 40 plus customers.

MTS continues to perform admirably and deliver quality product in a timely fashion. MTS received CE approval to treat non-union fractures with the LithoGold. Perhaps some of our shareholders could pursue this option in their hospitals as well. Let us know and we will show you the extensive nonunion clinical data and protocols. We average 85% success on tibia non unions with one treatment, even after 2 failed surgeries and 30 months of non-healing. This business is the same size as the kidney stone business. MTS also received approval to market the UroGold table top device for ED, Prostatitis, and incontinence. This is a great opportunity for us.

ISMST Research Meeting - Frankfurt

We just returned from Frankfurt Germany for the bi-annual research meeting of the ISMST. Nearly 30 presenters showed their latest research over two days. Nearly half of the presentations utilized our technology. The largest area of research was stem cell recruitment and differentiation. This was absolutely proven in numerous presentations from groups in Europe and Asia. Imagine a noninvasive technology that can trigger stem cell migration and activation from a patient's own bone marrow! The award for best presentation was presented to Marianne Koolen, of the Netherlands, for her work in Wnt signaling. Of course she used the DermaGold for her trials. They will soon enter a 3 year clinical trial for ankle arthrodesis with our technology that could lead to CE approval and reimbursement.

A multi-center, randomized, controlled study was presented that showed statistically significant improvement in heart function in European centers after the ischemic heart was treated with both stem cells and shockwaves. This publication and forthcoming European approval should prove beneficial to both TRT and CRT. The first research on spinal cord injuries was also presented with the results astounding the research teams. Several clinical studies will soon begin to support these findings.

TRANSITIONS

A NEWSLETTER FOR EQUITY HOLDERS OF TRT

Vol. 31 | March 2014

Milan 2014 ISMST

Everyone is encouraged to attend the next ISMST meeting in Milan Italy, June 26 -28. It will be hosted by the brilliant orthopedic surgeon, and shockwave expert, Dr. Christina d Augustina. Information can be found at ismst2014@gmail.com and www.ismst.com/congress.htm.



.....Of Interest



Congratulations to our colleague, Dr. Wolfgang Schaden, who has been promoted to adjunct Professor of the Ludwig Boltzmann Institute.

Conference attendees at the 2013 ISMST taking a break in beautiful Salzburg



Pictured below are attendees at the recent BRM Meeting



This newsletter is not an offer to sell or solicitation of an offer to buy TRT securities. Investment decisions should be based on the risks and disclosures presented in TRT's Confidential Memorandum. This newsletter contains forward-looking statements within the meaning of the federal securities laws. Forward-looking statements are only predictions and not guarantees of performance. You should not place undue reliance on any forward-looking statements.